Human care company Elekta AB (STO:EKTAB.ST) on Friday announced that the Odette Cancer Centre at Sunnybrook Health Sciences Centre, Totonto, has treated its first patient using Elekta Unity on 15 August 2019.
Reportedly, the patient is receiving treatment for a glioblastoma brain tumour.
According to the company, Elekta Unity is a transformative magnetic resonance radiation therapy (MR/RT) system that enables personalised precision radiation therapy. Elekta Unity combines a state-of-the-art 1.5T MRI scanner, a best-in-class 7 MV linear accelerator and breakthrough real-time adaptive radiotherapy software.
The combination of these technologies allows the radiation dose to be reshaped based on daily changes in shape, size and position of the tumour and surrounding healthy anatomy, as visualized with MRI and then enables accurate dose delivery with real-time visualisation of the tumour.
Elekta Unity had received clearance from the Canadian Nuclear Safety Commission just a few weeks ago.
Elekta Unity has CE-mark and 510(k) clearance and is not commercially available in all markets.
Elekta is a leader in precision radiation medicine.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886